secwatch.observer — SEC 8-K summary
======================================

Issuer:     LeonaBio, Inc. (LONA)
CIK:        0001620463
Form:       8-K
Filed at:   2026-01-09T23:59:59+00:00
Accession:  0001193125-26-008904
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.03, 7.01, 8.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Athira Pharma renames to LeonaBio (LONA); lasofoxifene Phase 3 >50% enrolled; CFO gets new severance
--------------------------------------------------------------------------------

- Name change to LeonaBio effective Jan 9, 2026; ticker to LONA on Nasdaq starting Jan 12.
- Phase 3 ELAINE-3 trial of lasofoxifene >50% enrolled; topline data expected mid-2027.
- CFO Robert Renninger entered amended change in control severance agreement; base salary increased to $460,000.
- Name change reflects Dec 2025 acquisition of lasofoxifene rights, with $90M upfront financing and potential additional $146M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1620463/000119312526008904/0001193125-26-008904-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1620463/000119312526008904/atha-20260107.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-008904

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer